IVANO Bioscience
Provider of validated pseudotyped viral particles, cell-free neutralization assay kits, and AAV packaging cell line technology for infectious disease research and gene therapy R&D. Offers custom pseudovirus production, per-batch functional quality control with accessible CoA and SDS documentation, and assays designed for BSL-2 or lower laboratory workflows.
Industries
Nr. of Employees
small (1-50)
IVANO Bioscience
Quebec, Quebec, Canada, North America
Products
Catalog of validated pseudotyped viral particles
Ready-to-use replication-defective pseudotyped particles displaying variant- or strain-specific viral envelope proteins for use in neutralization and infectivity assays; offered with reporter genes (luciferase default, GFP optional) and per-batch QC documentation (CoA and SDS).
Cell-free neutralization assay kit
Reagent kit that reproduces key virus–cell interactions using engineered particle components to detect functional neutralizing antibodies without live virus or cell culture; designed for rapid, mix-and-read workflows compatible with automated workstations.
rAAV packaging cell line platform
HEK293-based packaging cell line technology to generate AAV producer lines and produce recombinant AAV vectors for preclinical research, intended to reduce dependence on transient transfection methods.
SARS-CoV-2 Pseudovirus
Comprehensive neutralization assay solution pseudotyped with the Spike Glycoprotein of SARS-CoV-2 virus, Delta (B.1.617.2) variant, carrying a modified genome that expresses a luciferase reporter gene.
SARS-CoV-2 Pseudoviruses
SARS-CoV-2 pseudovirus reagents utilizing 3rd generation lentiviral vector and luciferase reporter system for neutralization assays.
SARS-CoV-2 Pseudovirus, BA.1 (Omicron) variant
SARS-CoV-2 pseudovirus featuring the Omicron (BA.1) variant spike glycoprotein and a firefly luciferase reporter, validated for transduction efficiency and neutralization assays.
Catalog of validated pseudotyped viral particles
Ready-to-use replication-defective pseudotyped particles displaying variant- or strain-specific viral envelope proteins for use in neutralization and infectivity assays; offered with reporter genes (luciferase default, GFP optional) and per-batch QC documentation (CoA and SDS).
Cell-free neutralization assay kit
Reagent kit that reproduces key virus–cell interactions using engineered particle components to detect functional neutralizing antibodies without live virus or cell culture; designed for rapid, mix-and-read workflows compatible with automated workstations.
rAAV packaging cell line platform
HEK293-based packaging cell line technology to generate AAV producer lines and produce recombinant AAV vectors for preclinical research, intended to reduce dependence on transient transfection methods.
SARS-CoV-2 Pseudovirus
Comprehensive neutralization assay solution pseudotyped with the Spike Glycoprotein of SARS-CoV-2 virus, Delta (B.1.617.2) variant, carrying a modified genome that expresses a luciferase reporter gene.
SARS-CoV-2 Pseudoviruses
SARS-CoV-2 pseudovirus reagents utilizing 3rd generation lentiviral vector and luciferase reporter system for neutralization assays.
SARS-CoV-2 Pseudovirus, BA.1 (Omicron) variant
SARS-CoV-2 pseudovirus featuring the Omicron (BA.1) variant spike glycoprotein and a firefly luciferase reporter, validated for transduction efficiency and neutralization assays.
Services
Feasibility assessment, production-parameter definition, scale-up testing, and manufacture of custom pseudotyped viral particles for neutralization and infectivity assays; options for co-development and special pricing for select projects.
Feasibility assessment, production-parameter definition, scale-up testing, and manufacture of custom pseudotyped viral particles for neutralization and infectivity assays; options for co-development and special pricing for select projects.
Expertise Areas
- Pseudotyped viral particle manufacturing
- Variant- and strain-specific pseudovirus productization
- Neutralization assay development (cell-free and cell-based)
- AAV packaging cell line development
Key Technologies
- Pseudotyped lentiviral particles
- VSV-based pseudovirus systems
- Virus-like particle components for cell-free assays
- Reporter gene assays (luciferase, GFP)
News & Updates
References to peer-reviewed articles that used pseudovirus neutralization assays as BSL-2-compatible methods for evaluating neutralizing antibodies and vaccine immunogenicity.
References to peer-reviewed articles that used pseudovirus neutralization assays as BSL-2-compatible methods for evaluating neutralizing antibodies and vaccine immunogenicity.